Plaque Psoriasis Treatment Medications - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032 Global Leading Market Research Publisher QYResearch announces the release of its latest report “Plaque Psoriasis Treatment Medications - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Plaque Psoriasis Treatment Medications market, including market size, share, demand, industry development status, and forecasts for the next few years. The global plaque psoriasis treatment medications market is entering a new stage of therapeutic diversification. Pharmaceutical companies are simultaneously addressing persistent challenges such as long-term disease control, treatment adherence, safety monitoring, patient preference for non-injectable therapies, and the need for higher clinical response rates. Against this background, biologics, small molecule drugs, and non-biologic drugs are evolving into complementary treatment pathways rather than isolated product categories. Recent regulatory developments have further expanded the competitive landscape, particularly with the emergence of targeted oral therapies. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5729308/plaque-psoriasis-treatment-medications Market Size, Disease Burden and Growth Outlook The global market for Plaque Psoriasis Treatment Medications was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. These market-value fields are presented exactly as supplied in the source material and require the full QYResearch report for the corresponding numerical estimates. Plaque psoriasis is the most common form of psoriasis, a chronic, relapsing autoimmune skin disease characterized by red, thickened patches covered with silvery-white scales. Its long-term nature creates recurring demand for topical, systemic and biologic treatment, while disease severity, comorbidities, treatment response and healthcare access influence medication selection. The underlying patient pool remains substantial. A recent analysis using Global Burden of Disease 2021 data estimated that global psoriasis prevalence increased from 23.06 million cases in 1990 to 42.98 million in 2021, an 86% increase, while incidence rose from 2.85 million to 5.10 million cases. (PubMed) Although these figures cover psoriasis as a whole rather than plaque psoriasis alone, they illustrate the expanding disease burden supporting long-term demand for effective treatment. From a market perspective, the most important structural trend is the continuing shift toward targeted therapies. Recent clinical literature indicates that IL-17 and IL-23 biologics provide particularly strong short-term probabilities of achieving PASI 90 responses in adults with moderate-to-severe plaque psoriasis, while oral therapies continue to serve patients who prefer non-injectable treatment options. (PubMed) Biologics Remain a Core Technology Segment Biologics represent a major component of the plaque psoriasis treatment medications market because they directly target specific immune pathways associated with psoriasis. The principal mechanisms include tumor necrosis factor (TNF) inhibition, IL-12/23 inhibition, IL-17 pathway inhibition and IL-23 inhibition. Established products include therapies such as adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab and risankizumab. The American Academy of Dermatology notes that biologics can be highly effective for moderate-to-severe psoriasis, while treatment selection requires consideration of safety, comorbidities, prior treatment response and patient-specific factors. (美国皮肤科学会) The competitive environment is also changing as biosimilars and expanded indications influence mature biologic franchises. For example, the FDA-approved labeling for IMULDOSA, a biosimilar to ustekinumab, includes moderate-to-severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy, as well as pediatric use in specified populations. (FDA Access Data) This creates a dual market dynamic: innovative biologics continue to compete on efficacy and dosing convenience, while biosimilars can broaden access and introduce additional pricing pressure. Small Molecule Drugs and the Shift Toward Oral Treatment Small molecule drugs provide an important alternative to injectable biologics. Their commercial value is linked not only to efficacy but also to administration convenience, patient preference and treatment accessibility. A particularly significant development occurred in March 2026, when the U.S. FDA approved ICOTYDE (icotrokinra), an oral IL-23 receptor antagonist, for moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The treatment is administered as a once-daily tablet. (U.S. Food and Drug Administration) The approval is strategically important because IL-23-targeted treatment had historically been strongly associated with injectable biologics. Icotrokinra demonstrates how the market is moving toward targeted oral therapies that seek to combine pathway specificity with greater convenience. The FDA reported that approval was supported by four clinical trials involving approximately 2,500 participants across 496 sites in 17 countries. (U.S. Food and Drug Administration) This development is likely to intensify competition between oral targeted therapies and established biologic platforms. Non-Biologic Drugs Continue to Serve Diverse Patient Needs Non-biologic drugs remain an essential part of plaque psoriasis treatment, particularly for patients with mild-to-moderate disease, patients requiring conventional systemic therapy, or individuals for whom biologic treatment is unsuitable. Topical corticosteroids remain widely used, while vitamin D analogues, tazarotene, calcineurin inhibitors, emollients and other topical agents can be incorporated into treatment strategies. The American Academy of Dermatology recommends topical corticosteroids for plaque psoriasis outside intertriginous areas and emphasizes the role of steroid-sparing approaches in chronic management. (美国皮肤科学会) Systemic non-biologic therapies also retain relevance. Methotrexate, cyclosporine and systemic retinoids have established clinical roles, although their use depends on disease characteristics, safety considerations and patient-specific circumstances. Consequently, the market should not be viewed as a simple replacement cycle in which biologics eliminate older therapies. Instead, treatment is increasingly structured around disease severity, treatment history, administration preferences and the balance between efficacy and safety. Hospital, Clinic and Other Application Channels By application, the market is segmented into Hospital, Clinic and Other channels. Hospitals remain important for patients with severe disease, complex comorbidities or treatment initiation requiring multidisciplinary assessment. Clinics and specialist dermatology practices represent another major channel because psoriasis management frequently involves long-term monitoring and treatment adjustment. The distinction between hospital and clinic demand also reflects the increasing complexity of personalized treatment. Dermatologists may evaluate disease severity using measures such as body surface area and physician global assessment, while PASI remains particularly important in clinical research. Quality-of-life instruments such as the Dermatology Life Quality Index can also contribute to treatment assessment. (美国皮肤科学会) A further consideration is safety monitoring. The 2026 joint position statement from the National Psoriasis Foundation Medical Board and International Psoriasis Council concluded that routine latent tuberculosis testing is not required for patients receiving IL-17 or IL-23 inhibitors, while noting exceptions such as certain immunosuppressive regimens and residence in tuberculosis-endemic areas. (PubMed) Such changes can influence clinical workflows and the total cost of treatment. Competitive Landscape and Key Market Participants The Plaque Psoriasis Treatment Medications market is segmented as below: Amgen, Allergan, Dermira, Eli Lilly, Novartis, Merck, Johnson & Johnson, Pfizer, AstraZeneca, AbbVie, LEO Pharma, Biogen, Galectin Therapeutics, Cellceutix, Bayer, Organon and UCB. The competitive landscape combines established multinational pharmaceutical companies with specialized biotechnology participants. Competition increasingly centers on biological pathway specificity, treatment durability, speed of response, dosing frequency, safety profile, pediatric expansion, patient convenience and reimbursement accessibility. The 2026 approval of icotrokinra illustrates the importance of mechanism innovation and administration format. Meanwhile, continued development of IL-17 and IL-23 therapies reinforces the importance of high-response targeted treatment. Pediatric expansion is another growth avenue: guselkumab, for example, received U.S. pediatric approvals in September 2025 for certain children aged six years and older with moderate-to-severe plaque psoriasis. (PubMed) Type and Application Segmentation Segment by Type Biologics Small Molecule Drugs Non-biologic Drugs These three categories reflect the industry's principal therapeutic technology routes. Biologics emphasize highly targeted immune modulation; small molecule drugs increasingly combine targeted mechanisms with oral administration; and non-biologic drugs remain fundamental for topical management and conventional systemic treatment. Segment by Application Hospital Clinic Other This segmentation highlights the different healthcare settings through which diagnosis, treatment initiation, medication administration and long-term disease management are delivered. Industry Outlook: From Drug Efficacy to Treatment Personalization The next phase of the plaque psoriasis treatment medications market is likely to be defined by treatment personalization rather than a single dominant therapeutic class. The central challenge for pharmaceutical companies is to develop therapies that deliver durable disease control while improving convenience and maintaining an acceptable safety profile. For manufacturers, this means that product differentiation will increasingly depend on multiple dimensions: molecular target, route of administration, dosing frequency, patient population, long-term safety evidence and real-world effectiveness. For healthcare providers, the growing number of treatment options creates a need for more individualized therapeutic decision-making. Overall, the 2026-2032 market outlook is shaped by an expanding disease burden, continuing innovation in biologic therapies, the emergence of targeted oral treatments, increasing pediatric treatment opportunities and ongoing competition among global pharmaceutical manufacturers. QYResearch's report provides a structured assessment of these market forces, historical performance from 2021-2025, competitive positioning and demand forecasts through 2032. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp